Skip to content

Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01482819
Enrollment
21
Registered
2011-12-01
Start date
2011-10-01
Completion date
2011-12-01
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

The purpose of this study is to evaluate corneal swelling, limbal redness, and endothelial bleb response to wearing galyfilcon A lenses in asian eyes.

Interventions

contact lenses worn bilaterally for 8-12 hours

DEVICEgalyfilcon A plus

contact lenses worn bilaterally for 8-12 hours

contact lenses worn bilaterally for 8-12 hours

DEVICEpolymacon

contact lenses worn bilaterally for 8-12 hours

OTHERspectacles

habitual spectacles owned by subject, non-specific manufacturer

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Be of legal age (i.e. 18 years) * Be of Asian descent and have -Asian eye‖ identifying features (see Appendix A) * Be mentally competent, willing and able to sign a written informed consent form. * Have contact lens distance sphere requirement in the range 1.00D to 6.00D. * Have spectacle astigmatism \<1.25D in each eye * Currently wear soft contact lenses (for at least 3 months prior to the trial ) without experiencing difficulties or contact lens related complications * Have had an oculo-visual examination within the previous 12 months. * Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having: * No evidence of lid abnormality or infection * No conjunctival abnormality or infection * No clinically significant slit lamp findings (i.e. edema, staining, scarring, vascularization, infiltrates or abnormal opacities) * No other active ocular disease

Exclusion criteria

* Requires concurrent ocular medication. * Clinically significant (Grade 3 or 4) corneal staining (FDA scale), corneal stromal haze, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear. * Has had refractive surgery. * Has had any anterior ocular surgery. Has had any other ocular surgery or injury within 8 weeks immediately prior to enrolment for this study. * History of abnormal lachrymal secretions. * Pre-existing ocular irritation that would preclude contact lens fitting. * Keratoconus or other corneal irregularity. * Extended lens wear in last 3 months. * PMMA, hybrid or RGP lens wear in the previous 8 weeks * Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear. * Has diabetes * Known/reported infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV). * History of chronic eye disease (e.g. glaucoma or ARMD). * Pregnancy, lactating, or planning a pregnancy at the time of enrolment. * Participation in any concurrent clinical trial or in last 30 days. * Family member or employee of the clinical site, investigator or other study staff. * Currently wears habitual contact lenses on an EW basis.

Design outcomes

Primary

MeasureTime frameDescription
Endothelia Blebsafter 20 minutes of lens wear0 to 100% of area; measured as a percentage of corneal area with blebs.
Corneal Swellingafter 8 hours of lens wearmeasured in microns using the Optical Low Coherence Reflectometry (OLCR) Pachymeter. This pachymeter gives corneal thickness measurements to the accuracy of 1 micron (µm)
Limbal Rednessafter 8 hours of lens weargrade scale of 0 to 4, where 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe; reported as an average grade.

Countries

Australia

Participant flow

Participants by arm

ArmCount
All Subjects
Twenty-one subjects were enrolled, and 19 subjects completed the study per protocol. Two subjects were discontinued. There were no ineligible subjects.
21
Total21

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyLost to Follow-up2

Baseline characteristics

CharacteristicAll Subjects
Age, Continuous23.7 years
STANDARD_DEVIATION 6.11
Race/Ethnicity, Customized
Asian
5 participants
Race/Ethnicity, Customized
Multiple
16 participants
Region of Enrollment
Australia
21 participants
Sex: Female, Male
Female
15 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 21
serious
Total, serious adverse events
0 / 21

Outcome results

Primary

Corneal Swelling

measured in microns using the Optical Low Coherence Reflectometry (OLCR) Pachymeter. This pachymeter gives corneal thickness measurements to the accuracy of 1 micron (µm)

Time frame: after 8 hours of lens wear

Population: Subjects who were enrolled, randomized, and completed the study. One eye from each subject was measured.

ArmMeasureValue (MEAN)Dispersion
SpectaclesCorneal Swelling569.42 micronsStandard Deviation 36.0709
Galyfilcon A PlusCorneal Swelling574.64 micronsStandard Deviation 39.7804
Galyfilcon ACorneal Swelling575.57 micronsStandard Deviation 37.6229
Lotrafilcon ACorneal Swelling578.99 micronsStandard Deviation 41.496
PolymaconCorneal Swelling573.79 micronsStandard Deviation 36.1644
Primary

Endothelia Blebs

0 to 100% of area; measured as a percentage of corneal area with blebs.

Time frame: after 20 minutes of lens wear

Population: Subjects who were enrolled, randomized and completed the study.

ArmMeasureValue (MEAN)Dispersion
SpectaclesEndothelia Blebs4.97 percentage of areaStandard Deviation 3.3703
Galyfilcon A PlusEndothelia Blebs8.86 percentage of areaStandard Deviation 3.9396
Galyfilcon AEndothelia Blebs10.93 percentage of areaStandard Deviation 6.602
Lotrafilcon AEndothelia Blebs10.31 percentage of areaStandard Deviation 6.6747
PolymaconEndothelia Blebs8.50 percentage of areaStandard Deviation 3.6
Primary

Limbal Redness

grade scale of 0 to 4, where 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe; reported as an average grade.

Time frame: after 8 hours of lens wear

Population: Subjects who were enrolled, randomized, and completed the study.

ArmMeasureValue (MEAN)Dispersion
SpectaclesLimbal Redness0.66 units on a scaleStandard Deviation 0.2479
Galyfilcon A PlusLimbal Redness0.83 units on a scaleStandard Deviation 0.3023
Galyfilcon ALimbal Redness0.77 units on a scaleStandard Deviation 0.3085
Lotrafilcon ALimbal Redness0.91 units on a scaleStandard Deviation 0.3087
PolymaconLimbal Redness1.14 units on a scaleStandard Deviation 0.3363

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026